Ang Hazel Xiaohui, Chan Sze Ling, Sani Levana L, Quah Clarissa Bernice, Brunham Liam R, Tan Boon Ooi Patrick, Winther Michael D
Genome Institute of Singapore, Agency for Science, Technology & Research, Singapore.
Translational Laboratory in Genetic Medicine, Agency for Science, Technology & Research, Singapore.
Pharmacogenomics. 2017 Jun;18(9):891-910. doi: 10.2217/pgs-2017-0009. Epub 2017 Jun 8.
While early pharmacogenomic studies have primarily been carried out in Western populations, there has been a notable increase in the number of Asian studies over the past decade. We systematically reviewed all pharmacogenomic studies conducted in Asia published before 2016 to highlight trends and identify research gaps in Asia. We observed that pharmacogenomic research in Asia was dominated by larger developed countries, notably Japan and Korea, and mainly driven by local researchers. Studies were focused on drugs acting on the CNS, chemotherapeutics and anticoagulants. Significantly, several novel pharmacogenomic associations have emerged from Asian studies. These developments are highly encouraging for the strength of regional scientific and clinical community and propound the importance of discovery studies in different populations.
虽然早期的药物基因组学研究主要在西方人群中进行,但在过去十年中,亚洲的研究数量有了显著增加。我们系统地回顾了2016年之前在亚洲进行的所有药物基因组学研究,以突出趋势并确定亚洲的研究差距。我们观察到,亚洲的药物基因组学研究主要由较大的发达国家主导,特别是日本和韩国,并且主要由当地研究人员推动。研究集中在作用于中枢神经系统的药物、化疗药物和抗凝剂上。值得注意的是,亚洲研究中出现了一些新的药物基因组学关联。这些进展对区域科学和临床界的实力非常鼓舞人心,并强调了在不同人群中进行发现性研究的重要性。